We reported in 2011 that at initial diagnosis of chronic-phase CML, imatinib recipients with high levels of CIP2A protein had a high actuarial risk of progression to blast crisis, and this was not associated with BCR-ABL1 kinase domain mutations [19]. This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.